PHARMACYTE BIOTECH, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $391.3K | $438.4K | $407.4K | $468.5K | $690.9K | $916.2K | $301.2K | $460.1K |
| SG&A Expense | $4.9M | $3.9M | $6.1M | $1.1M | $1.1M | $418.1K | $1.2M | $1.4M |
| Operating Income | $-6.9M | $-4.4M | $-8.5M | $-6.5M | $-4.4M | $-3.6M | $-3.8M | $-4.1M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | $0 | $509 | $3.0K | $453 | $0 |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | $-19.4M | $30.7M | $333.8K | $-4.3M | $-4.2M | $-3.6M | $-3.8M | $-4.1M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | $-2.77 | $3.19 | $-1.80 | $-0.22 | $-0.27 | $-0.22 | $-0.38 | $0.00 |
| EPS (Diluted) | $-2.77 | $3.19 | $-1.80 | $-0.22 | $-0.27 | $-0.22 | $-0.38 | $0.00 |
| Shares Outstanding (Basic) | 8.4M | 7.3M | 9.6M | 19.5M | 15.5M | 15.9M | 14.91B | 12.10B |
| Shares Outstanding (Diluted) | 8.4M | 7.3M | 9.6M | 19.5M | 15.5M | 15.9M | 14.91B | 12.10B |
| Dividends Per Share | — | — | — | — | — | — | — | — |